MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

Proteomes, published by MDPI since 2013, is a notable open access journal that occupies a critical place in the realms of Biochemistry, Clinical Biochemistry, Molecular Biology, and Structural Biology. Based in Switzerland, this journal not only promotes the dissemination of high-quality research pertaining to protein structures and functions but also emphasizes interdisciplinary approaches that bridge various fields of biomedical science. With a Category Quartile ranking of Q2 across multiple pertinent categories in 2023, Proteomes boasts a competitive impact within the scientific community, evidenced by its robust Scopus rankings. Researchers, professionals, and students are invited to explore a wealth of pioneering studies and reviews that are made freely accessible, aligning with global trends in open scientific communication. Whether contributing original research or seeking to expand their knowledge, the journal serves as an invaluable resource for anyone engaged in the evolving landscape of proteomics.

Biomarker Insights, published by SAGE Publications Ltd, is a leading open-access journal dedicated to advancing the field of biomarker research and its applications in health and disease. With an ISSN of 1177-2719 and an E-ISSN of 1177-2719, this journal has been at the forefront of disseminating high-quality scientific findings since its inception in 2006. Based in New Zealand, it has achieved a notable impact within the academic community, ranking in Q2 for Biochemistry (medical) and Molecular Medicine, and Q1 in Pharmacology as of 2023. This positions Biomarker Insights as a critical resource for researchers, professionals, and students alike, looking to explore innovative methodologies and applications in biomarker discovery and validation. With a commitment to open access, the journal ensures that groundbreaking research is readily available to the global community, fostering collaboration and innovation in the ever-evolving field of biomedical sciences.

PROTEOMICS is a leading journal focused on the rapidly evolving field of proteomics, published by WILEY in Germany. With a solid reputation established since its inception in 2001, it has continually contributed to the understanding of protein functions and interactions within biological systems. As part of its commitment to academic excellence, PROTEOMICS is ranked in the second quartile for both Biochemistry and Molecular Biology categories (2023), reflecting its significant influence in advancing research in these areas. Although it does not currently provide open access options, it remains a vital resource for researchers, professionals, and students keen to explore innovative methodologies and findings in proteomic research. By publishing groundbreaking studies that bridge theoretical knowledge with practical applications, PROTEOMICS plays a crucial role in enhancing our understanding of molecular processes and driving forward advancements in the life sciences.

Expert Review of Proteomics, published by TAYLOR & FRANCIS LTD, is a distinguished journal that focuses on the latest advancements in the field of proteomics, a critical area within biochemistry and molecular biology. With an ISSN of 1478-9450 and E-ISSN 1744-8387, this journal has been pivotal in disseminating high-quality research from its inception in 2004 to its planned convergence in 2024. Its influential position is reflected in its 2023 rankings, placing it in the Q2 category for both Biochemistry and Molecular Biology, alongside respectable Scopus rankings that rank it 118th and 141st in its respective categories. Despite its non-open access structure, Expert Review of Proteomics provides researchers and professionals with a vital platform for critical reviews and insights into proteomic methodologies, thus contributing significantly to the global scientific community. By bridging theoretical research with practical applications, it serves as an essential resource for those dedicated to advancing their knowledge and expertise in this dynamic field.

Precision Clinical Medicine, published by Oxford University Press, is an esteemed open-access journal that has been at the forefront of clinical research since its inception in 2018. With an ISSN of 2096-5303, this journal specializes in the rapidly evolving field of precision medicine, which aims to tailor healthcare to individual patient characteristics, needs, and preferences. As a testament to its influence, Precision Clinical Medicine holds a remarkable rank of #34 out of 636 in the General Medicine category on Scopus, placing it within the 94th percentile of its field and earning a prestigious Q1 rating in 2023. Based in the United Kingdom, the journal not only provides open access content, ensuring that groundbreaking research is widely disseminated, but also serves as a crucial platform for innovations and discussions that shape modern medical practices. Researchers, professionals, and students alike will find valuable insights and influential studies that drive the future of personalized healthcare within its pages.

Biomarker Research is a leading open access journal published by BMC, dedicated to advancing the field of biomarker discovery and clinical application. Since its inception in 2013, this journal has become a crucial resource for researchers and professionals in biochemistry, clinical biochemistry, and molecular medicine, achieving a prestigious Q1 ranking in each category in 2023. With an E-ISSN of 2050-7771, it maintains a strong reputation for disseminating high-quality research and innovative findings that contribute to the understanding of disease mechanisms and the development of novel diagnostics and therapeutics. The journal is accessible to a global audience, ensuring that vital research is freely available to promote collaboration and accelerate scientific progress. Operating out of the United Kingdom, Biomarker Research plays a significant role in addressing some of the most pressing challenges in medical research, making it an essential resource for academics, clinicians, and industry professionals alike.

Mass Spectrometry Letters is a pioneering open-access journal published by the Korean Society for Mass Spectrometry, specializing in the diverse fields of analytical chemistry, biochemistry, and spectroscopy. Established in 2010, this journal aims to disseminate groundbreaking research and advancements in mass spectrometry and its applications across various scientific domains. Though currently categorized in the Q4 quartile in key analytical fields, Mass Spectrometry Letters serves as an essential platform for researchers, professionals, and students to share innovative methodologies, emerging trends, and practical applications of mass spectrometry, thus fostering collaboration and advancing knowledge in the scientific community. With a commitment to open access, articles published since 2010 are readily available, enabling widespread distribution and engagement within the international research community. Located in Daejeon, South Korea, and actively converging research through 2024, the journal holds the potential to grow its impact and relevance within the dynamic landscape of mass spectrometry.

Clinical Proteomics is a leading open-access journal, published by BMC since 2011, that aims to advance the field of proteomics by providing a platform for the dissemination of original research, critical reviews, and technological advancements in the analysis of proteins and their roles in health and disease. With an ISSN of 1542-6416 and E-ISSN 1559-0275, this esteemed journal covers a broad scope, converging years of research from 2004 to 2024. As a distinguished publication, it holds a Q1 ranking in Clinical Biochemistry and Q2 in both Molecular Biology and Molecular Medicine, reflecting its significance in the scientific community. Clinical Proteomics' commitment to open access ensures that its content is readily available to researchers, professionals, and students worldwide, facilitating the exchange of knowledge and fostering collaborative efforts in proteomic studies. Situated in the United Kingdom, this journal plays a pivotal role in shaping the future of biomedical research, appealing to anyone keen on the integration of proteomics in clinical practice and molecular investigation.

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.